Oral GH secretagogue

MK-677

An oral ghrelin receptor agonist (ibutamoren) that raised growth hormone and IGF-1 in human trials, is not a component of an FDA-approved drug and is on the WADA Prohibited List.

Strong evidenceGet the app

Level after one dose

MK-677 after one dose: 50% at ~24 h, 25% at 48 h, 12.5% at 72 h.

Drawn from the half-life in the app's model, ~24 h. The model's figures

MK-677, also written MK 677, MK677 or MK-0677, is the research code for ibutamoren.1 FDA documents also call it ibutamoren mesylate and LUM-201.1 It is an orally available small-molecule agonist of the ghrelin receptor (GHSR) that stimulates the release of growth hormone.2,3,4 Merck Research Laboratories reported its synthesis.1

FDA states that ibutamoren mesylate is not a component of an FDA-approved drug.1 The TGA states that no product containing ibutamoren has been approved for supply in Australia.5 The WADA Prohibited List names ibutamoren (MK-677) among the prohibited growth hormone secretagogues.6 Trials from 1996 to 2018 reported that daily oral doses raised serum IGF-1 in older adults, obese men, adults and children with growth hormone deficiency, hip fracture patients, people with Alzheimer disease and haemodialysis patients.7,8,9,10,11,12,13 In the Alzheimer disease trial and the 2004 hip fracture trial there were no significant differences on the efficacy measures, and in the 2011 hip fracture trial stair climbing power did not differ significantly while gait speed did, before it was terminated early over a safety signal of congestive heart failure.11,12,14

In people

In 32 healthy people aged 64 to 81, 25 mg a day raised mean 24-hour growth hormone concentration by 97%, which the authors attributed to an enhancement of preexisting pulsatile GH secretion.7 Pulse height and the lowest concentrations between pulses rose significantly, without a significant change in the number of pulses.7 In a 1997 crossover trial of 8 young adults given 5 or 25 mg at bedtime for 7 days per period, high-dose treatment was followed by about 50% more stage IV sleep and more than 20% more REM sleep than placebo, and 6 older adults given 2 then 25 mg in 14-day periods had a nearly 50% increase in REM sleep associated with treatment.15 Over up to 4 weeks in older adults circulating cortisol did not change, while in the 2-year trial cortisol increased by 47 nmol/L.7,16

In cells, animals and structures

Ghrelin activates the ghrelin receptor GHSR to stimulate food intake and growth hormone secretion, and cryo-EM structures of the human receptor bound to ibutamoren were published in 2021.3 In rat pituitary cells in culture, L-163,191 (MK-0677) released GH with an EC50 of 1.3 nM and acted like GHRP-6, and in dogs oral doses as low as 0.125 mg/kg raised GH.17

3

Pharmacokinetics

Values from the Milligram app's model.

Half-life
~24 h
Bioavailability
95%
Typical dose
10–25 mg/day
Route
Oral
Table 3.1Pharmacokinetics6 rows
ParameterValueNote
Half-life~24 hoursNo measured plasma half-life is reported: FDA's 2024 evaluation quotes a 1997 statement that a single dose is long-acting (24 hours), which describes duration of action, and identified no further human pharmacokinetic data.1
Bioavailability (oral)~95%Source figure: oral bioavailability in dogs is reported as more than 60%, and FDA quotes a 1996 reference to high oral bioavailability in people without giving a human figure.1
Time to peak~2 hoursFDA's 2024 evaluation gives no time to peak.1
RouteOralNominated products were capsules or tablets of 10 mg and 25 mg.1
Typical dose10 to 25 mg/dayDoses used in trials: 2 mg to 50 mg per day and 0.2 mg/kg/day to 0.8 mg/kg/day, for up to 2 years, per FDA's summary.1
Markers to monitorIGF-1, blood glucose, insulinMeasured in trials: IGF-1 (a primary outcome in the dialysis and hip fracture trials), fasting glucose in older adults, and insulin in adults with growth hormone deficiency.

In obese men the GH and prolactin increases after the first dose were larger than after repeated doses, and significant increases persisted at 2 and 8 weeks except in peak prolactin.8 In a 1998 trial of 8 volunteers, peak GH was 55.9 micrograms/L after the first dose and 22.6 micrograms/L after a week of dosing, against about 9 and 7 micrograms/L on placebo.18 In equine liver microsomes, ibutamoren was metabolised primarily by oxidation and glucuronidation, as summarised by FDA.1

4

Human studies

Table 4.1Human studies10 rows
Study and yearDesignPeopleDose and lengthMain result
Chapman and colleagues, 19967Randomised, double-blind, placebo-controlled; no sponsor stated in the source text32 healthy people aged 64 to 812, 10 or 25 mg once daily, 14 and 28 daysAt 25 mg, IGF-I rose from 141 to 265 micrograms/L at 4 weeks and fasting glucose from 5.4 to 6.8 mmol/L.
Svensson and colleagues, 19988Randomised, double-blind, placebo-controlled; no sponsor stated in the source text24 obese men aged 18 to 5025 mg daily, 8 weeksFat-free mass increased; total and visceral fat did not change significantly; an oral glucose tolerance test showed impairment at 2 and 8 weeks.
Murphy and colleagues, 200119Randomised, double-blind, placebo-controlled, 18-month study; a Merck address for the corresponding author, no sponsor stated in the source text292 postmenopausal women aged 64 to 85 with low femoral neck bone density25 mg daily alone or with alendronate 10 mg, 12 months of the 18-month studyMK-677 alone raised osteocalcin 22% and urinary NTx 41% at month 12; with alendronate, femoral neck bone density rose 4.2% against 2.5% for alendronate, with no similar gain at the lumbar spine, total hip or total body.
Codner and colleagues, 200110Dose groups with a placebo week; no sponsor stated in the source text18 prepubertal children with GH deficiency0.2 or 0.8 mg/kg a day for 7 days, with a placebo weekAt 0.8 mg/kg, GH peak change was 3.8 micrograms/L (range 0 to 34.3, P = .001) and IGF-I change was 12 micrograms/L (range -4 to 116, P = .01); prolactin, glucose and insulin did not change.
Bach and colleagues, 200411Randomised, double-blind, placebo-controlled; Merck-affiliated authors161 hip fracture patients aged 65 and olderDaily for 6 months, 25 mg per FDA's summary1IGF-I rose 84% against 17% on placebo; no significant differences in functional performance measures or the overall Sickness Impact Profile score.
Nass and colleagues, 200816Two-year, randomised, double-blind, placebo-controlled, modified crossover; NIH-funded, with a Merck Research Laboratories affiliation among the authors71 randomised, 65 completed year 1; healthy, aged 60 to 8125 mg once daily, 2 years (primary endpoints at 12 months)At 12 months, fat-free mass, a primary endpoint, changed -0.5 kg on placebo and +1.1 kg on MK-677; abdominal visceral fat, the other primary endpoint, rose 4.2 cm2 on placebo and 8.4 cm2 on MK-677 (P = 0.68); limb fat rose 1.1 kg against 0.24 kg; strength and function did not change.
Sevigny and colleagues, 200812Double-blind, multicentre; Merck-affiliated authors563 patients with mild to moderate Alzheimer disease25 mg daily, 12 monthsIGF-1 rose 60.1% at 6 weeks and 72.9% at 12 months; no significant differences on the CIBIC-plus, ADAS-Cog, ADCS-ADL or CDR-sob.
Adunsky and colleagues, 201114Randomised, double-blind, multicentre phase IIb; no sponsor stated in the source text123 hip fracture patients, 62 on MK-067725 mg a day, planned 24 weeks; stopped earlyTerminated early over a safety signal of congestive heart failure; stair climbing power did not differ significantly (p = 0.292), gait speed did (p = 0.011), and IGF-1 rose 51.4 ng/ml in treated patients.
Campbell and colleagues, 201813Randomised, double-blind crossover; no sponsor stated in the source text26 haemodialysis patients enrolled, 22 completed3-month crossoverIGF-1 increase was 65% greater than with placebo; no serious adverse effects attributable to MK-0677.
Massachusetts General Hospital pilot, started August 202220Open-label, with historical placebo controls; sponsor Massachusetts General Hospital12 adults with BMI 25 or more and fatty liver disease; 7 completed25 mg daily, 6 monthsThe primary outcome, change in liver fat, was +3.9 points with ibutamoren against +6.6 points in 10 historical placebo participants (p = 0.4).

Clinical results were mixed: the 2-year trial met its fat-free mass endpoint and missed its visceral fat endpoint, the Alzheimer disease and 2004 hip fracture trials reported no significant differences on their efficacy measures, and the liver fat pilot did not show a significant change against historical controls.16,12,11,20 The authors of the 2-year trial wrote that its duration and participant number were insufficient to evaluate functional end points in healthy older people.16 FDA's 2024 evaluation concluded that there is insufficient information to support the effectiveness of ibutamoren mesylate for the treatment of growth hormone deficiency, osteoporosis, hip fracture, sarcopenia, obesity and Alzheimer disease.1

5

Doses reported in studies and on labels

Table 5.1Doses reported in studies and on labels12 rows
SourceDoseFrequencyLength
Chapman and colleagues, 19962, 10 or 25 mgOnce daily14 and 28 days
Chapman and colleagues, 199710 or 50 mgOnce daily4 days
Svensson and colleagues, 199825 mgDaily8 weeks
Murphy and colleagues, 200125 mg, alone or with alendronate 10 mgDaily12 months
Codner and colleagues, 20010.2 or 0.8 mg/kgPer day7 days
Bach and colleagues, 200425 mg, per FDA's summary1Once daily6 months
Nass and colleagues, 200825 mgOnce daily2 years
Sevigny and colleagues, 200825 mgDaily12 months
Adunsky and colleagues, 201125 mgPer dayPlanned 24 weeks; stopped early
Massachusetts General Hospital pilot25 mgDaily6 months
FDA evaluation, nominated productsCapsules or tablets of 10 mg and 25 mgNot statedNot stated
TGA advisory, product label of one brand's ("Pharmatech") unapproved capsules15 mg of ibutamoren per capsule on the labelNot statedNot stated

In the 2-year trial in healthy older adults, increased appetite was reported in 29 of 43 people on MK-677 (67%) and 8 of 22 on placebo (36%), and in 50% of those on MK-677 appetite returned to normal within 3 months and more gradually in others.16 Edema was recorded in 44% on MK-677 and 27% on placebo (P = 0.3), muscle pain in 33% and 9% (P = 0.1), and joint pain in 58% on MK-677 and 77% on placebo.16 Fasting glucose rose by an average of 0.3 mmol/L on MK-677 and insulin sensitivity decreased, and body weight rose 2.7 kg on MK-677 and 0.8 kg on placebo.16 A 68-year-old woman had a myocardial infarction 7 days after starting MK-677, and an 82-year-old woman on MK-677 was diagnosed with adenocarcinoma of the tongue at 12 months.16 One man on placebo was diagnosed with renal cell carcinoma at 6 months.16

The 2011 hip fracture trial was terminated early over a safety signal of congestive heart failure, which FDA's summary puts at 4 patients (6.5%) on MK-0677 against 1 (1.7%) on placebo, with serious adverse events in 24% against 13%.14,1 In the 2004 hip fracture trial, FDA's summary lists serious adverse events in 24% against 18% and four thromboses on MK-0677 against none on placebo, reported as not drug related.1 In the Alzheimer disease trial, FDA's summary quotes drug-related clinical adverse experiences in 35.5% on MK-677 and 23.9% on placebo, with blood glucose raised in 15.4% against 4.6% and HbA1C in 11.1% against 1.4%.1 In the 12-person liver fat pilot, no serious events or deaths were reported, and increased appetite occurred in 7, hyperglycemia in 4, fatigue in 3, joint pain in 3 and hypertension in 2.20

A case report describes transaminitis after 2 months of MK-677 that returned to normal limits after stopping the supplement.21 FDA's December 2025 warning letter lists increased appetite, water retention, fatigue, muscle pain, potential alterations in glucose metabolism and insulin sensitivity, and a potential increase in congestive heart failure risk in certain individuals.4 A TGA laboratory test found undeclared metandienone in one brand's ("Pharmatech") unapproved MK-677 capsules, whose label stated 15 mg of ibutamoren.5

IGF-1 was the primary outcome of the haemodialysis trial and one of two primary outcomes of the 2011 hip fracture trial; in the 4-week trial in older adults at 25 mg a day it reached young-adult concentrations, and fasting glucose rose in the same trial.13,14,7 In the Alzheimer disease trial, IGF-1 was 72.9% higher at 12 months.12 Fasting glucose rose from 5.4 to 6.8 mmol/L at 4 weeks in older adults at 25 mg a day and by 0.3 mmol/L on average in the 2-year trial; in obese men fasting glucose was unchanged while an oral glucose tolerance test showed impairment.7,16,8 In adults with growth hormone deficiency, fasting and postprandial insulin and postprandial glucose rose, and the authors wrote that the clinical significance of these changes would need assessing in longer term studies.9 In the 2-year trial LDL cholesterol rose 0.12 mmol/L on placebo and fell 0.14 mmol/L on MK-677 (P = 0.026), with no difference between groups in total or HDL cholesterol.16

FDA's 2024 evaluation states that ibutamoren mesylate is not a component of an FDA-approved drug and, written for the 503A bulk drug substances list, found that the balance of criteria weighs against placing it on that list.1 In a December 2025 warning letter, FDA called ibutamoren an active ingredient not approved by FDA and concluded that it is excluded from the dietary supplement definition.4 The TGA's June 2026 advisory states that no product containing ibutamoren has been approved for supply in Australia.5 A phase 3 trial of daily oral LUM-201 in prepubertal children with growth hormone deficiency, with Lumos Pharma as lead sponsor, started in May 2026, with primary completion estimated for December 2027, and a Massachusetts General Hospital record names LUM-201 as ibutamoren mesylate.22,20

The WADA 2026 Prohibited List, in effect from 1 January 2026, names ibutamoren (MK-677) in S2.2.4 as an example of growth hormone secretagogues and their mimetics.6 Class S2 is prohibited at all times, in and out of competition, and its substances are non-specified substances.6

9

Storage and handling

FDA's evaluation states that there is no applicable USP or NF drug substance monograph for ibutamoren mesylate.1 It reports that certificates of analysis from two nominators gave storage at room temperature or at 2 to 8 degrees Celsius without a stability period, and that a literature search found no stability or degradation data for either condition.1

FDA's evaluation identified no human pharmacokinetic data beyond two qualitative statements, so a human plasma half-life, time to peak and route of elimination for ibutamoren are not stated in it.1 The studies ran from 4 days to 2 years, with cohorts from 6 older adults in a sleep study to 563 people in the Alzheimer disease trial.9,16,15,12 A review of growth hormone secretagogues states that the safety of these compounds with long-term use, including evaluation of cancer incidence and mortality, is needed.2 FDA noted that older people with high IGF-1 levels have been observed to be at increased risk for incident disease or death, and stated that there is a lack of safety data on risks associated with higher IGF-1 levels with ibutamoren.1

11

Frequently asked questions

What is MK-677?

MK-677 is the research code for ibutamoren, an orally available small-molecule ghrelin receptor agonist that stimulates growth hormone release and is not a component of an FDA-approved drug. Source: FDA evaluation of ibutamoren mesylate, 2024.

What is the half-life of MK-677?

No measured plasma half-life is reported: FDA's 2024 evaluation quotes a 1997 statement that a single dose is long-acting (24 hours), which describes duration of action. Source: FDA evaluation of ibutamoren mesylate, 2024.

What did IGF-1 do over 4 weeks in the 1996 older-adult trial?

In older adults taking 25 mg once daily, mean serum IGF-I rose from 141 micrograms/L at baseline to 219 at 2 weeks and 265 at 4 weeks, and fasting glucose rose from 5.4 to 6.8 mmol/L at 4 weeks. Source: Chapman and colleagues, Journal of Clinical Endocrinology and Metabolism, 1996.

What dose of MK-677 was used in trials?

Among the trials in the tables above, those of 24 weeks or longer gave 25 mg a day where a dose is stated, shorter trials gave 2 to 50 mg a day, and the children's trial gave 0.2 and 0.8 mg/kg a day. Source: FDA's summary of the trials, 2024.

What did the 2-year trial find on body composition?

At 12 months, fat-free mass (a primary endpoint) changed -0.5 kg on placebo and +1.1 kg on MK-677, abdominal visceral fat (the other primary endpoint) did not differ significantly, limb fat rose 1.1 kg against 0.24 kg, and strength and function did not change. Source: Nass and colleagues, Annals of Internal Medicine, 2008.

What are the side effects of MK-677 in trials?

In the 2-year trial, increased appetite was reported in 67% on MK-677 against 36% on placebo and edema in 44% against 27%, fasting glucose rose by 0.3 mmol/L, and a 2011 hip fracture trial was terminated early over a safety signal of congestive heart failure. Sources: Nass and colleagues, 2008, and Adunsky and colleagues, 2011.

Is MK-677 banned in sport?

Yes: the WADA 2026 Prohibited List names ibutamoren (MK-677) in S2.2.4, in a class prohibited at all times. Source: WADA Prohibited List 2026.

13

References

  1. US Food and Drug Administration. FDA evaluation of ibutamoren mesylate for the 503A bulk drug substances list. Briefing document, Pharmacy Compounding Advisory Committee, 29 October 2024. FDA briefing document
  2. Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev 2018. PMID 28400207
  3. Liu H, et al. Structural basis of human ghrelin receptor signaling by ghrelin and the synthetic agonist ibutamoren. Nat Commun 2021. PMID 34737341
  4. US Food and Drug Administration. Warning letter to Agebox Inc., 19 December 2025. FDA warning letter
  5. Therapeutic Goods Administration. Unapproved ibutamoren capsules (MK-677) found to contain undisclosed anabolic steroid. Safety advisory, 4 June 2026. TGA advisory
  6. World Anti-Doping Agency. Prohibited List 2026, in effect from 1 January 2026. WADA list
  7. Chapman IM, et al. Stimulation of the GH-IGF-I axis by daily oral MK-677 in healthy elderly subjects. J Clin Endocrinol Metab 1996. PMID 8954023
  8. Svensson J, et al. Two-month treatment of obese subjects with MK-677. J Clin Endocrinol Metab 1998. PMID 9467542
  9. Chapman IM, et al. Oral MK-677 and the GH/IGF-I axis in selected GH-deficient adults. J Clin Endocrinol Metab 1997. PMID 9329386
  10. Codner E, et al. Oral ibutamoren mesylate and the GH-IGF-I axis in GH-deficient children. Clin Pharmacol Ther 2001. PMID 11452249
  11. Bach MA, et al. The effects of MK-0677 in patients with hip fracture. J Am Geriatr Soc 2004. PMID 15066065
  12. Sevigny JJ, et al. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology 2008. PMID 19015485
  13. Campbell GA, et al. Oral MK-0677 increases serum IGF-1 in hemodialysis patients. Nephrol Dial Transplant 2018. PMID 28340044
  14. Adunsky A, et al. MK-0677 (ibutamoren mesylate) in patients recovering from hip fracture: a phase IIb study. Arch Gerontol Geriatr 2011. PMID 21067829
  15. Copinschi G, et al. Prolonged oral treatment with MK-677 and sleep quality in man. Neuroendocrinology 1997. PMID 9349662
  16. Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med 2008. PMID 18981485
  17. Patchett AA, et al. Design and biological activities of L-163,191 (MK-0677). Proc Natl Acad Sci USA 1995. PMID 7624358
  18. Murphy MG, et al. MK-677 reverses diet-induced catabolism. J Clin Endocrinol Metab 1998. PMID 9467534
  19. Murphy MG, et al. Alendronate and MK-677, alone and combined, in postmenopausal osteoporotic women. J Clin Endocrinol Metab 2001. PMID 11238495
  20. Massachusetts General Hospital. The impact of ibutamoren on nonalcoholic fatty liver disease: a pilot study. ClinicalTrials.gov record with posted results, 2024. NCT05364684
  21. Cobani E, et al. Hepatotoxicity induced by MK-677. BMJ Case Rep 2025. PMID 40675653
  22. Lumos Pharma. Phase 3 study of LUM-201 in children with growth hormone deficiency. ClinicalTrials.gov NCT06948214, 2026. NCT06948214